Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas

Luigi Scotto, Marianna Kruithof-De Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, Owen A. O'Connor

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To generate a transgenic mouse that when crossed with spontaneous mouse models of lymphoma will allow for quantitative in vivo measurement of tumor burden over the entire spectrum of the disease and or response to therapy in a "disease" or lymphoma subtype-specific manner. Experimental Design: We developed a novel genetically engineered transgenic mouse using a Cherry-Luciferase fusion gene targeted to the CD19 locus to achieve B-cell-restricted fluorescent bioluminescent emission in transgenicmousemodels of livingmice. The use of a dual function protein enables one to link the in vivo analysis via bioluminescence imaging to cell discriminating ex vivo analyses via fluorescence emission. Results: The spatiotemporal tracking of B-cell lymphoma growth and the response of an established B-cell lymphoma to a drug known to induce remission was evaluated in a double transgenic animal obtained by crossing the CD19CherryLuciferase transgenic mouse to a mouse model of an aggressive B-cell lymphoma. The observations validated the use of the CD19CherryLuciferase transgenic mouse in the assessment of an active drug routinely used in the treatment of lymphoproliferative malignancies. Conclusions: The transgenic mouse described here is the first of its kind, intended to be used to hasten translational studies of novel agents in lymphoma, with the intent that understanding the relevant pharmacology before clinical study will accelerate successful development in clinical studies.

Original languageEnglish (US)
Pages (from-to)3803-3811
Number of pages9
JournalClinical Cancer Research
Volume18
Issue number14
DOIs
StatePublished - Jul 15 2012
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Transgenic Mice
Lymphoma
Genetically Modified Animals
Gene Fusion
Tumor Burden
Luciferases
Pharmaceutical Preparations
B-Lymphocytes
Research Design
Fluorescence
Pharmacology
Growth
Neoplasms
Proteins
Clinical Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas. / Scotto, Luigi; Kruithof-De Julio, Marianna; Paoluzzi, Luca; Kalac, Matko; Marchi, Enrica; Buitrago, Jairo Baquero; Amengual, Jennifer; Shen, Michael M.; O'Connor, Owen A.

In: Clinical Cancer Research, Vol. 18, No. 14, 15.07.2012, p. 3803-3811.

Research output: Contribution to journalArticle

Scotto, L, Kruithof-De Julio, M, Paoluzzi, L, Kalac, M, Marchi, E, Buitrago, JB, Amengual, J, Shen, MM & O'Connor, OA 2012, 'Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas', Clinical Cancer Research, vol. 18, no. 14, pp. 3803-3811. https://doi.org/10.1158/1078-0432.CCR-11-2588
Scotto, Luigi ; Kruithof-De Julio, Marianna ; Paoluzzi, Luca ; Kalac, Matko ; Marchi, Enrica ; Buitrago, Jairo Baquero ; Amengual, Jennifer ; Shen, Michael M. ; O'Connor, Owen A. / Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 14. pp. 3803-3811.
@article{94cf009883a5455cbe200b75234c2a0e,
title = "Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas",
abstract = "Purpose: To generate a transgenic mouse that when crossed with spontaneous mouse models of lymphoma will allow for quantitative in vivo measurement of tumor burden over the entire spectrum of the disease and or response to therapy in a {"}disease{"} or lymphoma subtype-specific manner. Experimental Design: We developed a novel genetically engineered transgenic mouse using a Cherry-Luciferase fusion gene targeted to the CD19 locus to achieve B-cell-restricted fluorescent bioluminescent emission in transgenicmousemodels of livingmice. The use of a dual function protein enables one to link the in vivo analysis via bioluminescence imaging to cell discriminating ex vivo analyses via fluorescence emission. Results: The spatiotemporal tracking of B-cell lymphoma growth and the response of an established B-cell lymphoma to a drug known to induce remission was evaluated in a double transgenic animal obtained by crossing the CD19CherryLuciferase transgenic mouse to a mouse model of an aggressive B-cell lymphoma. The observations validated the use of the CD19CherryLuciferase transgenic mouse in the assessment of an active drug routinely used in the treatment of lymphoproliferative malignancies. Conclusions: The transgenic mouse described here is the first of its kind, intended to be used to hasten translational studies of novel agents in lymphoma, with the intent that understanding the relevant pharmacology before clinical study will accelerate successful development in clinical studies.",
author = "Luigi Scotto and {Kruithof-De Julio}, Marianna and Luca Paoluzzi and Matko Kalac and Enrica Marchi and Buitrago, {Jairo Baquero} and Jennifer Amengual and Shen, {Michael M.} and O'Connor, {Owen A.}",
year = "2012",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-11-2588",
language = "English (US)",
volume = "18",
pages = "3803--3811",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas

AU - Scotto, Luigi

AU - Kruithof-De Julio, Marianna

AU - Paoluzzi, Luca

AU - Kalac, Matko

AU - Marchi, Enrica

AU - Buitrago, Jairo Baquero

AU - Amengual, Jennifer

AU - Shen, Michael M.

AU - O'Connor, Owen A.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - Purpose: To generate a transgenic mouse that when crossed with spontaneous mouse models of lymphoma will allow for quantitative in vivo measurement of tumor burden over the entire spectrum of the disease and or response to therapy in a "disease" or lymphoma subtype-specific manner. Experimental Design: We developed a novel genetically engineered transgenic mouse using a Cherry-Luciferase fusion gene targeted to the CD19 locus to achieve B-cell-restricted fluorescent bioluminescent emission in transgenicmousemodels of livingmice. The use of a dual function protein enables one to link the in vivo analysis via bioluminescence imaging to cell discriminating ex vivo analyses via fluorescence emission. Results: The spatiotemporal tracking of B-cell lymphoma growth and the response of an established B-cell lymphoma to a drug known to induce remission was evaluated in a double transgenic animal obtained by crossing the CD19CherryLuciferase transgenic mouse to a mouse model of an aggressive B-cell lymphoma. The observations validated the use of the CD19CherryLuciferase transgenic mouse in the assessment of an active drug routinely used in the treatment of lymphoproliferative malignancies. Conclusions: The transgenic mouse described here is the first of its kind, intended to be used to hasten translational studies of novel agents in lymphoma, with the intent that understanding the relevant pharmacology before clinical study will accelerate successful development in clinical studies.

AB - Purpose: To generate a transgenic mouse that when crossed with spontaneous mouse models of lymphoma will allow for quantitative in vivo measurement of tumor burden over the entire spectrum of the disease and or response to therapy in a "disease" or lymphoma subtype-specific manner. Experimental Design: We developed a novel genetically engineered transgenic mouse using a Cherry-Luciferase fusion gene targeted to the CD19 locus to achieve B-cell-restricted fluorescent bioluminescent emission in transgenicmousemodels of livingmice. The use of a dual function protein enables one to link the in vivo analysis via bioluminescence imaging to cell discriminating ex vivo analyses via fluorescence emission. Results: The spatiotemporal tracking of B-cell lymphoma growth and the response of an established B-cell lymphoma to a drug known to induce remission was evaluated in a double transgenic animal obtained by crossing the CD19CherryLuciferase transgenic mouse to a mouse model of an aggressive B-cell lymphoma. The observations validated the use of the CD19CherryLuciferase transgenic mouse in the assessment of an active drug routinely used in the treatment of lymphoproliferative malignancies. Conclusions: The transgenic mouse described here is the first of its kind, intended to be used to hasten translational studies of novel agents in lymphoma, with the intent that understanding the relevant pharmacology before clinical study will accelerate successful development in clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=84863890062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863890062&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2588

DO - 10.1158/1078-0432.CCR-11-2588

M3 - Article

C2 - 22589392

AN - SCOPUS:84863890062

VL - 18

SP - 3803

EP - 3811

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -